NCT04116411View on ClinicalTrials.gov

A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Valganciclovir Tablets

Valganciclovir treatment of glioblastoma

DRUG

Temozolomide 120 mg

Chemotherapy

RADIATION

Radiotherapy 60 Gy

Radiation therapy

DRUG

Placebo oral tablet

Placebo treatment of glioblastoma

Trial Locations (3)

Unknown

RECRUITING

Oslo University Hospital, Oslo

RECRUITING

Stavanger University Hospital, Stavanger

SE17164

RECRUITING

SE01 Karolinska University Hospital, Solna

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

lead

Cecilia Soderberg-Naucler

OTHER